COMPARISON OF THE PHARMACOKINETICS AND SAFETY OF LIQUID (30 µg) AND LYOPHILIZED TETRODOTOXIN (15 µg AND 30 µg) FOLLOWING SINGLE AND TWICE DAILY SUBCUTANEOUS DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS—DETERMINATIONS IN BLOOD AND URINE.

Trial Profile

COMPARISON OF THE PHARMACOKINETICS AND SAFETY OF LIQUID (30 µg) AND LYOPHILIZED TETRODOTOXIN (15 µg AND 30 µg) FOLLOWING SINGLE AND TWICE DAILY SUBCUTANEOUS DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS—DETERMINATIONS IN BLOOD AND URINE.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Tetrodotoxin (Primary)
  • Indications Arrhythmias; Cancer pain; Neuropathic pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Sep 2016 Results assessing safety presented at the 16th World Congress on Pain
    • 07 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 07 Feb 2012 Actual initiation date (December 2011) and actual patient no 44 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top